20150075.TNBC
— · A
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- A
- subtype
- A
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.550
- G2M_CHECKPOINT+0.490
- MYC_TARGETS_V2+0.360
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.350
- UNFOLDED_PROTEIN_RESPONSE+0.350
- REACTIVE_OXYGEN_SPECIES_PATHWAY+0.310
- ANGIOGENESIS+0.280
- TNFA_SIGNALING_VIA_NFKB+0.280
- INTERFERON_ALPHA_RESPONSE+0.260
- IL6_JAK_STAT3_SIGNALING+0.250
Top 10 suppressed
- ESTROGEN_RESPONSE_EARLY-0.420
- ESTROGEN_RESPONSE_LATE-0.370
- APICAL_SURFACE-0.250
- PROTEIN_SECRETION-0.250
- OXIDATIVE_PHOSPHORYLATION-0.210
- PEROXISOME-0.160
- BILE_ACID_METABOLISM-0.140
- KRAS_SIGNALING_DN-0.140
- P53_PATHWAY-0.130
- HEME_METABOLISM-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A1OW-01A-21R-A144-07 | — | E | 0.801 |
| 2 | DRR168594 | — | — | 0.799 |
| 3 | GSM5359424 | — | — | 0.794 |
| 4 | 4d36189e-fe88-4cfb-970b-a51b8e9e0783 | — | — | 0.747 |
| 5 | 20040077.TNBC | — | E | 0.740 |
| 6 | SRR12202482 | — | — | 0.739 |
| 7 | R418 | — | — | 0.723 |
| 8 | TCGA-A2-A0CM-01A-31R-A034-07 | — | E | 0.722 |
| 9 | TCGA-A2-A0D2-01A-21R-A034-07 | — | E | 0.722 |
| 10 | SRR934852 | — | — | 0.715 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 33 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.550 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.490 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.360 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.350 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.350 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.310 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.280 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.260 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_UP | 0.230 | Idelalisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.210 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.200 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.190 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.180 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.160 | Idelalisib | — uncovered |
| HYPOXIA | 0.150 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.150 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.140 | Idelalisib | — uncovered |